Amisulpride: Difference between revisions
No edit summary |
|||
| Line 140: | Line 140: | ||
The elimination half-life is approximately 12 hours. | The elimination half-life is approximately 12 hours. | ||
|} | |||
==Drug Management== | |||
===Monitoring=== | |||
The following populations must be closely monitored after administration of amisulpride: | |||
*Elderly persons with susceptibility to drowsiness, confusion, and unsteadiness, which may increase the risk of fall | |||
*Patients with severe liver and/or renal failure because of the risk of accumulation. | |||
*Patients on long-term treatment should receive regular eye examinations. | |||
*Diabetic patients should get monitoring blood sugar levels during treatment. | |||
*May cause increased susceptibility to sunburn and individuals should avoid undue exposure to direct sunlight. | |||
*changes in mood, the development or worsening depression, and/or any thoughts or behaviour of suicide. | |||
*Be careful while taking antihistamines (chlorpheniramine), sleeping tablets while taking this medicine. Ampisulpride can increase drowsiness caused by medicines affecting the nervous system. | |||
*Tell the doctor if notice any of the following: | |||
-Abnormal movements of the face or tongue | |||
-Yellowing of the skin and eyes, that is jaundice | |||
-Muscle twitching | |||
-An absence of monthly periods for 6 months or more | |||
===Drug interaction=== | |||
The most common interactions encountered with amisulpride result from use with drugs that have similar pharmacological actions, for example: | |||
Amisulpride may aggravate Parkinsonism and antagonize the action of levodopa. | |||
{| class="wikitable" | |||
!style="text-align: left"| Drugs given with amisulpride | |||
!style="text-align: left"| Potential Effect | |||
|- | |||
|style="text-align: left"| | |||
*•CNS-depressant drugs including alcohol, hypnotics, anxiolytics, sedative H1 antihistamines, central antihypertensives, baclofen, thalidomide and opioids. | |||
| | |||
Potentiates the sedative effect. | |||
|- | |||
|style="text-align: left"| | |||
•Antipsychotics such as clozapine | |||
| | |||
Imprudent to combine antipsychotics due to additive risk for tardive dyskinesia and neuroleptic malignant syndrome. | |||
|- | |||
|style="text-align: left"| | |||
*Lithium | |||
|Increased risk of extrapyramidal side-effects when antipsychotics given with lithium. | |||
|- | |||
|style="text-align: left"| | |||
*•Antiparkinsonian drugs (amantadine, bromocriptine, levodopa, ropinirole) | |||
|Antipsychotics with dopamine-blocking activity and dopaminergic drugs such as those used to treat parkinsonism may be mutually antagonistic. | |||
|- | |||
|style="text-align: left"| | |||
*Drugs that prolong the QT interval e.g. amiodarone, sotalol, quinidine | |||
*Drugs which induce bradycardia e.g. diltiazem, verapamil | |||
*Drugs which can cause hypokalaemia such as diuretics e.g. frusemide | |||
|An increased risk of ventricular arrhythmias – avoid concomitant use. | |||
|} | |} | ||
Revision as of 00:14, 28 October 2020
Amisulpride(中文:[[ ]]) is an atypical antipsychotic or 2nd Generation antipsychotic medication. It is used to treat acute and chronic schizophrenia, in which
- positive symptoms (such as delusions, hallucinations, thought disorders) and/or
- negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent.
Pronunciation
Amisulpride 100mg
Amisulpride 400mg
Drug Names
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Amisulpride Tab 100 mg | AMIS01 | P1S1S3 |
| Amisulpride Tab 200 mg | AMIS02 | P1S1S3 |
| Amisulpride Tab 400 mg | AMIS04 | P1S1S3 |
Mechanism of Action
Amisulpride selectively blocks dopamine D2 receptors in the brain. It has no affinity for serotonic, α-adrenergic, histamine H1 and cholinergic receptors. The effectiveness of amisulpride in treating the negative symptoms of schizophrenia is due to its blockade of the presynaptic dompamine D2 receptors. By blocking them amisulpride increases dopamine concentrations in the synapse. This increased dopamine is theorized to act on dopamine D1 receptors to relieve the negative symptoms of schizophrenia.
Dosage
| Indication | Dose |
|---|---|
| Acute psychotic episode in Schizophrenia | By mouth
ADULT:
|
| Schizophrenia with predominantly negative symptoms | By mouth
ADULT:
|
How long does it take for Amisulpride to work?
The patient may start to feel better in a short time but it can take as long as 6 to 8 weeks before the benefits of this medicine is noticed.
Side Effects
It produces a moderate degree of extrapyramidal symptoms (EPS. These symptoms include:
- Drooling/trouble swallowing
- Restlessness/constant need to move
- Shaking (tremor)
- Shuffling walk
- Stiff muscles
- Severe muscle spasms/cramping (such as twisting neck, arching back, eyes rolling up)
- Mask-like expression of the face
- Tardive dyskinesia (any uncontrollable movements such as lip smacking, mouth puckering, tongue thrusting, chewing, or unusual arm/leg movements
Other adverse effects include the following:
| Endocrine disorders |
Common: hyperprolactinaemia (elevated levels of the hormone prolactin, which for females may result in
For males it may result in
Rare: benign pituitary tumour such as prolactinoma |
|---|---|
| Muscle/Nervous system disorders: |
Common:
-Tremor -Akathisia -Parkinsonism -hypersalivation
-Dry mouth -Constipation -Blurred vision
Uncommon: tardive dyskinesia and seizures Rare:
|
| Metabolism disorders |
Uncommon: hyperglycemia Rare:
|
| Cardiac disorders |
Common: hypotension Rare:
|
| Hypersensitivity reactions | Increased sensitivity to the sun or notice symptoms of sunburn (such as redness, swelling, blistering) which may occur more quickly than normal |
| Investigations |
Common:
|
Pharmacokinetics
| Oral bioavailability | It is readily absorbed after oral doses. |
|---|---|
| Onset of action | It shows two absorption peaks: one is attained rapidly, one hour post-dose and a second between 3 and 4 hours after administration.
Peak plasma concentrations are reached 1.5 – 6 hours after an oral dose. |
| Metabolism | It is metabolized in the liver |
| Elimination half-life |
It is predominantly eliminated in the urine. The elimination half-life is approximately 12 hours. |
Drug Management
Monitoring
The following populations must be closely monitored after administration of amisulpride:
- Elderly persons with susceptibility to drowsiness, confusion, and unsteadiness, which may increase the risk of fall
- Patients with severe liver and/or renal failure because of the risk of accumulation.
- Patients on long-term treatment should receive regular eye examinations.
- Diabetic patients should get monitoring blood sugar levels during treatment.
- May cause increased susceptibility to sunburn and individuals should avoid undue exposure to direct sunlight.
- changes in mood, the development or worsening depression, and/or any thoughts or behaviour of suicide.
- Be careful while taking antihistamines (chlorpheniramine), sleeping tablets while taking this medicine. Ampisulpride can increase drowsiness caused by medicines affecting the nervous system.
- Tell the doctor if notice any of the following:
-Abnormal movements of the face or tongue -Yellowing of the skin and eyes, that is jaundice -Muscle twitching -An absence of monthly periods for 6 months or more
Drug interaction
The most common interactions encountered with amisulpride result from use with drugs that have similar pharmacological actions, for example:
Amisulpride may aggravate Parkinsonism and antagonize the action of levodopa.
| Drugs given with amisulpride | Potential Effect |
|---|---|
|
Potentiates the sedative effect. |
|
•Antipsychotics such as clozapine |
Imprudent to combine antipsychotics due to additive risk for tardive dyskinesia and neuroleptic malignant syndrome. |
|
Increased risk of extrapyramidal side-effects when antipsychotics given with lithium. |
|
Antipsychotics with dopamine-blocking activity and dopaminergic drugs such as those used to treat parkinsonism may be mutually antagonistic. |
|
An increased risk of ventricular arrhythmias – avoid concomitant use. |
